Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management of prolactinomas.

P Nomikos1, M Buchfelder, R Fahlbusch

  • 1Department of Neurosurgery, University of Erlangen-Nürnberg, Germany. nomikos@nch.imed.uni-erlangen.de

Journal of Neuro-Oncology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ENDOCRINE DISTURBANCES IN PARASELLAR MENINGIOMAS AND THE EFFECT OF TRANSSPHENOIDAL DECOMPRESSION OPERATIONS.

Acta endocrinologica (Bucharest, Romania : 2005)·2026
Same author

Microsurgical treatment of cranial and spinal dural arteriovenous fistulas for acute occlusion: a single institution's experience.

Neurological research·2022
Same author

Typing of inflammatory lesions of the pituitary.

Pituitary·2021
Same author

ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy.

European journal of endocrinology·2021
Same author

The optimal surgical techniques for pituitary tumors.

Best practice & research. Clinical endocrinology & metabolism·2019
Same author

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.

Endocrine-related cancer·2019

Prolactinomas, a common pituitary tumor, are often treated with dopamine agonists. Surgery offers a high remission rate, especially for microprolactinomas, making it a viable alternative to lifelong medication.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Prolactinomas are the most frequent pituitary adenomas.
  • Medical treatment with dopamine agonists is standard, leading to tumor shrinkage and normalized prolactin levels.
  • Symptoms include menstrual dysfunction, galactorrhea, and sexual dysfunction, or mass effects on surrounding structures.

Purpose of the Study:

  • To evaluate the efficacy of surgical treatment for prolactinomas.
  • To determine factors influencing surgical remission rates.
  • To assess surgical treatment as an alternative to long-term medical management.

Main Methods:

  • Retrospective analysis of 540 surgically treated prolactinoma cases.
  • Evaluation of transsphenoidal surgery outcomes.

Related Experiment Videos

  • Correlation of preoperative prolactin levels, tumor size, and extension with remission rates.

    • Main Results:

    • Overall remission rates in surgical series range from 54% to 86%.
    • In this series of 540 patients, the remission rate was 82% for microprolactinomas with preoperative prolactin levels <200 ng/ml.
    • Surgical success is dependent on preoperative prolactin levels, tumor size, and extension.

    Conclusions:

    • Transsphenoidal surgery is an effective treatment for prolactinomas.
    • High remission rates, particularly in microprolactinomas, suggest surgery as a potential alternative to lifelong medical therapy.
    • Surgical intervention should be considered, especially for patients with high prolactin levels or large tumors unresponsive to medical management.